A more reliable treatment decision with gene expression
Prostatype was developed by researchers at Karolinska Institutet and developed to provide more reliable measures of how aggressive a prostate cancer is. The test improves the ability to predict survival and provides a more reliable answer as to whether treatment is needed or not.
The test analyzes the expression of genes in cancer cells from prostate tissue. Together with Gleason, PSA value and tumor stage, Prostatype then calculates a P-score; a more reliable measure of how aggressive prostate cancer is.
A more reliable statement
Prostate cancer is the most common form of cancer in Sweden. In some cases it is difficult to detect when it is aggressive and should be treated, and in many cases we treat with surgery without it being necessary. It is difficult to determine with certainty how serious a prostate cancer is and many surgeries cause serious side effects.
With Prostatype, you can give your patient a more reliable statement. The result provides a more accurate basis and an additional basis for a second opinion. You as a doctor get better control over the patient’s diagnosis and an important piece of the puzzle before the important decision about the patient’s treatment.